extended release metformin

Phase 2

extended release metformin is one of 6 therapeutic programs targeting Mild Cognitive Impairment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Mild Cognitive ImpairmentActive, not recruiting

ErythroplakiaActive, not recruiting

Mild Cognitive ImpairmentPreclinical

Active, not recruiting

ErythroplakiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Mild Cognitive Impairment

#DrugCompanyPhaseTrials

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 2

extended release metformin

CColumbia University

Phase 2

1 3

Senicapoc

IIcagen

Phase 2

1 4

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 5

Quercetin

MMayo Clinic

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Erythroplakia

NCT05237960

Q2 2027

PreclinicalActive, not recruiting

Mild Cognitive Impairment

NCT04098666

Clinical

Trials by Indication[1]

Erythroplakia1 trial

M4OC-Prevent 2.0: Phase IIb Trial of Metformin for Oral Cancer Prevention

Active, not recruiting·UUniversity of Arizona·Phase 2·NCT05237960·34 enrolled

Mild Cognitive Impairment1 trial

Metformin in Alzheimer's Dementia Prevention

Active, not recruiting·CColumbia University·Preclinical·NCT04098666·326 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for extended release metformin. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for extended release metformin. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Columbia University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: CColumbia University

extended release metformin

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Erythroplakia1 trial

Mild Cognitive Impairment1 trial

References

Drug Info

Quick Facts

Related News